Trial reportPhytotherapy research : PTR2026
Ashwagandha ( Withania somnifera ) Root Extract Improves General Health in Elderly Men and Women: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study.
Trial report in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunomodulatory Properties of Withania somnifera: Regulation of Innate Immune Cells and Clinical Implications.Phytotherapy research : PTR · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ashwagandha (Withania somnifera), an adaptogen, is widely used in traditional Indian medicine for its health benefits in elderly people with functional limitations and physical disabilities. This double-blind, randomized, placebo-controlled clinical trial study assessed the efficacy and safety of a standardized Ashwagandha Root Extract (ARE) on general health improvement in elderly. Fifty (32 male, 18 female) healthy people aged between 60 and 85 years who consented to participate were randomly assigned to receive either capsule ARE 300 mg twice daily orally (n = 25) or an identical placebo (n = 21) for 8 weeks. The primary efficacy outcome was change in scores for Older People's Quality of Life (OPQOL) questionnaire, whereas secondary outcomes were change in scores for the Epworth Sleepiness Scale (ESS), and Senior Fitness Test (SFT). Clinical safety was evaluated using adverse events and global assessment of tolerability to therapy (GATT) by the physician. Greater improvement in OPQOL scores was observed with ARE, compared to placebo at both week 4 (p = 0.023) and week 8 (p < 0.0001), and these differences were observed in all sub-scales of OPQOL. Patients receiving ARE showed higher improvements after week 8 for total scores for ESS (p < 0.001), and SFT sub-scales (p < 0.01). The majority of participants on ARE reported excellent to good tolerability (96.0%). No adverse events were reported in the ARE group, while one patient reported nausea and headache in the placebo group. Ashwagandha root extract can be a useful herbal intervention for the improvement of general health and quality of life in elderly men and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.